Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a combination of three separate medications rather than a single formulated combination drug. Each component has its own distinct properties and uses. ## Colchicine Colchicine is indicated for the prophylaxis and treatment of gout flares, Familial Mediterranean fever (FMF), and to reduce the risk of cardiovascular events in patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease[4]. It's also used off-label for conditions like Behcet's syndrome and pericarditis[4]. ## Diclofenac Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It has a moderate drug interaction with sulfasalazine, where diclofenac may decrease the therapeutic efficacy of sulfasalazine[1][3]. ## Sulfasalazine Sulfasalazine is indicated for treating mild to moderate ulcerative colitis, prolonging remission between acute attacks, and as an adjunct therapy in severe ulcerative colitis[1]. The delayed-release formulation is also indicated for rheumatoid arthritis in certain pediatric patients[1]. It's sometimes used off-label for Crohn's disease, distal ulcerative colitis, and proctitis[1]. ## Drug Interactions There are notable interactions between these medications: - Diclofenac can decrease the therapeutic efficacy of sulfasalazine when used in combination[1][3]. - Sulfasalazine has 271 known drug interactions in total, with 46 major, 216 moderate, and 9 minor interactions[2]. - Patients with certain conditions may need to use these medications with caution, as sulfasalazine has 12 disease interactions including colitis, liver disease, renal dysfunction, and folate deficiency[2]. The combination of these three medications would need careful monitoring due to their individual side effect profiles and potential interactions. This is not a standard fixed-dose combination product but rather three separate medications that might be prescribed together for specific clinical situations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Colchicine, Diclofenac, and Sulfasalazine (Combination).